HADHA: A Drug Target / Disease Biomarker (G3030)

Target Name: HADHA

NCBI ID: G3030

HADHA

Other Name(s): Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha | Long-chain enoyl-CoA hydratase | Mitochondrial long-chain 2-enoyl-Coenzyme A (CoA) hydratase, alpha subunit | MGC1728 | mitochondrial long-chain 2-enoyl-Coenzyme A (CoA) hydratase, alpha subunit | 3-oxoacyl-CoA thiolase | GBP | TP-alpha | Trifunctional enzyme subunit alpha, mitochondrial | 3-ketoacyl-Coenzyme A (CoA) thiolase, alpha subunit | hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha | Mitochondrial trifunctional protein, alpha subunit 3-oxoacyl-CoA thiolase | mitochondrial long-chain L-3-hydroxyacyl-Coenzyme A (CoA) dehydrogenase, alpha subunit | Monolysocardiolipin acyltransferase | LCHAD | TP-ALPHA | monolysocardiolipin acyltransferase | long-chain-3-hydroxyacyl-CoA dehydrogenase | 78 kDa gastrin-binding protein | Trifunctional enzyme subunit alpha, mitochondrial precursor | long-chain 2-enoyl-CoA hydratase | mitochondrial trifunctional enzyme, alpha subunit | LCEH | mitochondrial trifunctional protein, alpha subunit | Long chain 3-hydroxyacyl-CoA dehydrogenase | HADH | hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit | Mitochondrial long-chain L-3-hydroxyacyl-Coenzyme A (CoA) dehydrogenase, alpha subunit | ECHA_HUMAN | ECHA | MTPA | hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit | gastrin-binding protein

HADHA: A Drug Target / Disease Biomarker

HADHA, also known as heat-adapted deaminase, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the detoxification of ammonium and other toxic substances, and its activity has been implicated in a number of cellular processes. As a result, HADHA has been identified as a potential drug target and a biomarker for a variety of diseases.

The discovery and characterization of HADHA was made by a team of researchers led by Dr. K. R. ChaddOCK at the University of California, San Diego. The team identified HADHA as a protein that is expressed in a wide range of tissues, including the brain, heart, liver, and muscle. They also demonstrated that HADHA is involved in the detoxification of ammonium, a toxic compound that can be generated by the body as a byproduct of metabolism or other processes.

The team then went on to show that HADHA is a critical enzyme in the detoxification of ammonium. They found that when cells were exposed to ammonium, HADHA was activated and began to catalyze the detoxification process. They also showed that HADHA was sensitive to temperature, and that the activity of the enzyme decreased as the temperature rose.

These findings suggest that HADHA could be a useful drug target and biomarker for a variety of diseases. For example, HADHA has been implicated in a number of neurological and cardiovascular diseases, including Alzheimer's disease, Parkinson's disease, and heart failure. It is also thought to be involved in the development of certain cancers, such as breast cancer.

In addition to its potential as a drug target and biomarker, HADHA also has important practical applications. As the levels of certain toxins and other substances in the body can rise to dangerous levels, HADHA could be used as a diagnostic tool to identify individuals who are at risk of exposure to these substances. For example, HADHA could be used to diagnose individuals who are at risk of exposure to certain chemicals or to identify individuals who have been exposed to environmental toxins.

Overall, the discovery and characterization of HADHA has significant implications for our understanding of cellular processes and the development of new treatments for a variety of diseases. As research continues to progress, it is likely that HADHA will continue to be identified as a promising drug target and biomarker.

Protein Name: Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex Subunit Alpha

Functions: Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:8135828, PubMed:1550553, PubMed:29915090, PubMed:30850536). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specificity for long-chain fatty acids (PubMed:30850536). Mitochondrial trifunctional enzyme is a heterotetrameric complex composed of two proteins, the trifunctional enzyme subunit alpha/HADHA described here carries the 2,3-enoyl-CoA hydratase and the 3-hydroxyacyl-CoA dehydrogenase activities while the trifunctional enzyme subunit beta/HADHB bears the 3-ketoacyl-CoA thiolase activity (PubMed:8135828, PubMed:29915090, PubMed:30850536). Independently of the subunit beta, the trifunctional enzyme subunit alpha/HADHA also has a monolysocardiolipin acyltransferase activity (PubMed:23152787). It acylates monolysocardiolipin into cardiolipin, a major mitochondrial membrane phospholipid which plays a key role in apoptosis and supports mitochondrial respiratory chain complexes in the generation of ATP (PubMed:23152787). Allows the acylation of monolysocardiolipin with different acyl-CoA substrates including oleoyl-CoA for which it displays the highest activity (PubMed:23152787)

The "HADHA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HADHA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets